FY2026 Earnings Estimate for CryoPort Issued By KeyCorp

CryoPort logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • KeyCorp forecasts CryoPort FY2026 EPS of a loss of $0.88 per share, matching the current consensus, and estimates a $0.17-per-share loss in Q4 2026 and a $0.60-per-share loss in FY2027. It maintains an “Overweight” rating and a $20 price target.
  • CryoPort reported quarterly EPS of a loss of $0.25, missing the $0.18 loss analysts expected, while revenue of $50.22 million exceeded the $48.66 million consensus.
  • Analyst sentiment is broadly positive: seven analysts rate the stock a Buy and two a Hold, for a “Moderate Buy” consensus and an average price target of $21.69.
  • MarketBeat previews the top five stocks to own by December 1st.

CryoPort, Inc. (NASDAQ:CYRX - Free Report) - KeyCorp issued their FY2026 earnings per share estimates for CryoPort in a report released on Thursday, November 5th. KeyCorp analyst P. Knight forecasts that the company will post earnings per share of ($0.88) for the year. KeyCorp has an "Overweight" rating and a $20.00 price objective on the stock. The consensus estimate for CryoPort's current full-year earnings is ($0.88) per share. KeyCorp also issued estimates for CryoPort's Q4 2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.60) EPS.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). CryoPort had a negative return on equity of 8.28% and a negative net margin of 21.46%. The firm had revenue of $50.22 million for the quarter, compared to the consensus estimate of $48.66 million.

CYRX has been the topic of a number of other reports. Piper Sandler raised shares of CryoPort to a "buy" rating in a report on Tuesday, October 13th. Robert W. Baird set a $26.00 price target on shares of CryoPort in a research note on Tuesday, October 13th. Roth Capital reaffirmed a "buy" rating and set a $21.00 price target on shares of CryoPort in a research note on Friday, August 7th. Guggenheim lifted their price target on shares of CryoPort from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Finally, Weiss Ratings raised shares of CryoPort from a "sell (d)" rating to a "hold (c-)" rating in a research note on Thursday, October 8th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $21.69.

Check Out Our Latest Stock Analysis on CYRX

CryoPort Price Performance

Shares of NASDAQ CYRX opened at $19.89 on Monday. The company has a 50 day simple moving average of $17.43 and a 200 day simple moving average of $13.70. The firm has a market cap of $1.01 billion, a PE ratio of -20.50 and a beta of 1.89. CryoPort has a 1 year low of $7.61 and a 1 year high of $21.78.

Insider Transactions at CryoPort

In related news, insider Mark W. Sawicki sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $19.93, for a total value of $199,300.00. Following the sale, the insider directly owned 92,356 shares in the company, valued at $1,840,655.08. This represents a 9.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Daniel Hancock sold 74,379 shares of the company's stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $20.21, for a total value of $1,503,199.59. Following the completion of the sale, the director owned 69,052 shares in the company, valued at $1,395,540.92. The trade was a 51.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CYRX. State of Alaska Department of Revenue bought a new stake in shares of CryoPort in the 3rd quarter valued at $40,000. State of Wyoming acquired a new stake in shares of CryoPort during the third quarter worth $81,000. Highland Investment Advisors LLC acquired a new stake in shares of CryoPort during the second quarter worth $306,000. Counterpoint Mutual Funds LLC acquired a new stake in shares of CryoPort during the third quarter worth $324,000. Finally, Diversified Trust Co raised its stake in CryoPort by 3.4% during the third quarter. Diversified Trust Co now owns 19,769 shares of the company's stock worth $344,000 after buying an additional 657 shares during the last quarter. Institutional investors own 92.90% of the company's stock.

CryoPort Company Profile

(Get Free Report)

Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company's services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CryoPort Right Now?

Before you consider CryoPort, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.

While CryoPort currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines